CA3003077A1 - Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells - Google Patents

Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells Download PDF

Info

Publication number
CA3003077A1
CA3003077A1 CA3003077A CA3003077A CA3003077A1 CA 3003077 A1 CA3003077 A1 CA 3003077A1 CA 3003077 A CA3003077 A CA 3003077A CA 3003077 A CA3003077 A CA 3003077A CA 3003077 A1 CA3003077 A1 CA 3003077A1
Authority
CA
Canada
Prior art keywords
cells
delta
gamma
tissue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003077A
Other languages
English (en)
French (fr)
Inventor
Adrian Hayday
Oliver NUSSBAUMER
Richard Woolf
Original Assignee
Kings College London
Cancer Research Technology Ltd
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1519198.4A external-priority patent/GB201519198D0/en
Priority claimed from GBGB1612731.8A external-priority patent/GB201612731D0/en
Application filed by Kings College London, Cancer Research Technology Ltd, Francis Crick Institute Ltd filed Critical Kings College London
Publication of CA3003077A1 publication Critical patent/CA3003077A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
CA3003077A 2015-10-30 2016-10-31 Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells Pending CA3003077A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1519198.4 2015-10-30
GBGB1519198.4A GB201519198D0 (en) 2015-10-30 2015-10-30 Expansion of gamma delta t cells resident in non-haematopoietic tissue and uses of these cells
GB1612731.8 2016-07-22
GBGB1612731.8A GB201612731D0 (en) 2016-07-22 2016-07-22 Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
PCT/EP2016/076264 WO2017072367A1 (en) 2015-10-30 2016-10-31 EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS

Publications (1)

Publication Number Publication Date
CA3003077A1 true CA3003077A1 (en) 2017-05-04

Family

ID=57211532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003077A Pending CA3003077A1 (en) 2015-10-30 2016-10-31 Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells

Country Status (16)

Country Link
US (2) US11618885B2 (enExample)
EP (2) EP3368658B1 (enExample)
JP (3) JP2018533373A (enExample)
KR (2) KR20250093576A (enExample)
CN (1) CN108473958A (enExample)
AU (2) AU2016344779B2 (enExample)
CA (1) CA3003077A1 (enExample)
DK (1) DK3368658T3 (enExample)
ES (1) ES2925261T3 (enExample)
IL (3) IL295838B2 (enExample)
MX (2) MX2018005207A (enExample)
MY (1) MY198084A (enExample)
PH (1) PH12018500926A1 (enExample)
PL (1) PL3368658T3 (enExample)
PT (1) PT3368658T (enExample)
WO (1) WO2017072367A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP3681996B1 (en) 2017-09-15 2024-08-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2020027193A1 (ja) * 2018-07-31 2020-02-06 国立大学法人三重大学 γδ型Ｔ細胞への遺伝子導入方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CN113423820A (zh) * 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
PH12021551475A1 (en) 2019-01-07 2022-05-02 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN112029719B (zh) * 2019-06-04 2024-05-03 北京医明佳和生物科技有限公司 纯化的双阴性t细胞及其制备和应用
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
WO2023053994A1 (ja) * 2021-09-29 2023-04-06 アイ ピース， インコーポレイテッド 幹細胞の製造方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
JPWO2023176896A1 (enExample) * 2022-03-18 2023-09-21
EP4504247A1 (en) 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
CN121532496A (zh) 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法
CN118165933B (zh) * 2024-05-14 2024-07-16 成都美杰赛尔生物科技有限公司 组合物、提高cd39-cd69-t细胞比例的方法
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
CN118853566B (zh) * 2024-09-26 2025-05-09 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养方法及培养基

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421573T1 (de) 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20060246520A1 (en) * 2003-05-23 2006-11-02 Institut National De La Sante Et De La Recherche Medicale Gamma delta t cell-mediated therapy
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
PT2710123T (pt) * 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CN104293734B (zh) * 2014-09-28 2018-01-09 上海云舜生物技术有限公司 一种人γδT细胞的制备方法
CN104711224A (zh) * 2015-01-09 2015-06-17 天津大学 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2016198906A1 (fr) * 2015-06-10 2016-12-15 Arcelormittal Acier a haute résistance et procédé de fabrication

Also Published As

Publication number Publication date
ES2925261T3 (es) 2022-10-14
US20180312808A1 (en) 2018-11-01
JP2018533373A (ja) 2018-11-15
PH12018500926A1 (en) 2018-11-05
IL295838A (en) 2022-10-01
US20230099491A1 (en) 2023-03-30
EP4148124A1 (en) 2023-03-15
MX2018005207A (es) 2018-09-19
AU2016344779A1 (en) 2018-06-14
HK1253954A1 (en) 2019-07-05
CN108473958A (zh) 2018-08-31
US11618885B2 (en) 2023-04-04
MX2022011003A (es) 2022-10-07
WO2017072367A1 (en) 2017-05-04
IL315329A (en) 2024-10-01
IL295838B2 (en) 2025-02-01
IL258985B2 (en) 2023-02-01
KR20180098235A (ko) 2018-09-03
RU2018119684A3 (enExample) 2020-03-17
KR102821381B1 (ko) 2025-06-13
JP2024069306A (ja) 2024-05-21
JP7451468B2 (ja) 2024-03-18
EP3368658B1 (en) 2022-07-06
KR20250093576A (ko) 2025-06-24
EP3368658A1 (en) 2018-09-05
PL3368658T3 (pl) 2022-11-28
DK3368658T3 (da) 2022-08-01
AU2022283768A1 (en) 2023-02-02
MY198084A (en) 2023-07-31
RU2018119684A (ru) 2019-12-02
IL258985B (en) 2022-10-01
IL295838B1 (en) 2024-10-01
BR112018008293A2 (en) 2018-10-30
PT3368658T (pt) 2022-08-17
JP2022002517A (ja) 2022-01-11
AU2016344779B2 (en) 2023-01-05
IL258985A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US20230099491A1 (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
US12458698B2 (en) Expansion of γδ T cells, compositions, and methods of use thereof
HK40090397A (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
RU2784566C2 (ru) РАЗМНОЖЕНИЕ И ПРИМЕНЕНИЕ НЕГЕМОПОЭТИЧЕСКИХ ТКАНЕРЕЗИДЕНТНЫХ γδ Т-КЛЕТОК
HK1253954B (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EA049808B1 (ru) ЭКСПАНСИЯ γΔ-Т-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112018008293B1 (pt) Método in vitro para a expansão de células t gama delta não hematopoiéticas
EA044224B1 (ru) ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211027

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240815

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240930

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250409

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250409

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250515

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250929

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D135 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST RECEIVED

Effective date: 20260114

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D136 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST AUTHORIZED

Effective date: 20260114

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED

Effective date: 20260114